• Explore /
  • Poster
  • / Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.

Efficacy and safety of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma (HCC): A randomized phase II trial.

Abstract Poster

Authors

null

Ann-Lii Cheng

National Taiwan University Hospital, Taipei, Taiwan

Ann-Lii Cheng , Chia-Jui Yen , Tae-You Kim , Yin-Hsun Feng , Yee Chao , Deng-Yn Lin , Arsene-Bienvenu Loembe , Julia Hocke , Caren Choi , Baek-Yeol Ryoo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT00987935

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 339)

DOI

10.1200/jco.2015.33.3_suppl.339

Abstract #

339

Poster Bd #

C8

Abstract Disclosures

Similar Posters

First Author: Tim Meyer

First Author: Arndt Vogel

First Author: Masatoshi Kudo

First Author: Daniel H. Palmer